Merck & Co.’s $6.7 billion bid for Terns Pharmaceuticals took Wall Street by surprise, both because of its timing and the lower-than-anticipated price being paid for a much-heralded treatment that could reshape treatment of chronic myeloid leukemia.
Terns’ drug, called TERN-701, is a type of targeted, oral treatment that’s shown early potential to challenge marketed therapies, like Novartis’ Scemb...
Steelman: Merck & Co.'s acquisition of Terns Pharmaceuticals for $6.7 billion represents a strategic move to bolster its oncology portfolio with an innovative oral treatment for Chronic Myeloid Leukemia (CML). The deal captures the potential sales revenue of TERN-701 in the U.S., assuming no pricing restrictions from Medicare and market exclusivity that extends into the 2040s.
Patterns detected: ARC-0043 Motte-and-Bailey, ARC-0024 Ambiguity (The article presents the acquisition price as a potent...